ABT-806: Phase I started

Abbott began a 6-month, open-label, dose-ranging Phase I trial to evaluate IV ABT-806 in up to 30 patients. Abbott has rights to the compound from Life Science under a 2008 deal (see BioCentury, Nov. ...